DOI: https://doi.org/10.22141/2308-2097.53.3.2019.181467

Optimizing of duodenogastric reflux therapy in patients with chronic gastritis

O.O. Hutsalenko

Abstract


Background. The known methods of duodenogastric reflux treatment which include prokinetics administration against the background of chronic gastritis standard therapy, as a rule, have the low therapeutic efficacy. The aim of the research was to assess the efficacy and safety of metoclopramide and sulpiride combination (dual prokinetic treatment) for duodenogastric reflux in comprehensive treatment of patients with chronic gastritis. Materials and methods. The study is based on the retrospective analysis of the findings obtained while examining and managing 30 patients with duodenogastric reflux and chronic gastritis aged from 22 to 45 years. The patients received treatment in accordance with the Standardized Clinical Protocol of Primary Care “Dyspepsia”, approved by the Order of the Ministry of Health of Ukraine No. 600 of August 3, 2012, and recommended by Maastricht III (2005) and Maastricht IV (2010). The basic therapy for chronic gastritis was combined with two drugs of synergistic effect, namely, prokinetic metoclopramide and sulpiride with prokinetic properties by similar principle in the regimen of short-term step therapy. The statistical processing of data was carried out according to the algorithm for qualitative data analysis with MedCalc 2019 software package. The study includes the analysis of manifestation incidence of qualitative binary variables with calculation of 95% confidence interval. When determining the effect of dual prokinetic treatment on the change of clinical syndromes manifestation incidence, we used McNemar test for related groups. The study evaluated the risk of side effects of metoclopramide and eglonil combination on the basis of assessment the significance value 95% confidence interval, considering binominal distribution of a sign (presence or absence of complication). The study presented formulation of the null and alternative statistical hypotheses. Results. The manifestations of dyspeptic, abdominal and astheno-vegetative syndromes were detected in 24 ((80.0 ± 7.3) %; 95% CI 51.26–119.03 %), 13 ((43.00 ± 9.04) %; 95% CI 23.07–74.10 %) and 18 patients ((60.00 ± 8.94) %; 95% CI 35.56–94.83 %), respectively. After 20 days of dual prokinetic treatment, the statistically significant changes in the incidence of dyspeptic, abdominal and astheno-vegetative syndromes manifestations were observed in patients against the background of endoscopic signs of bile reflux elimination (bilateral values p < 0.0001; p = 0.0005 and p < 0.0001, respectively, according to the McNemar test). The synergism of metoclopramide and eglonil effect as dopamine receptor antagonists and prokinetic effect potentiation in combination with standard therapy contribute to the rapid elimination of the most clinical manifestations of the bile reflux syndrome, make it possible to achieve clinical and endoscopic recovery and ensure steady and long-term remission. The tolerability of drug combinations was good in all patients; they did not present with side effects. Moreover, the risk of side effects did not exceed 12 % with 95% probability. Conclusions. The short-term administration of metoclopramide and sulpiride combination in step therapy regimen is not only effective but also safe, which corresponds to the alternative statistical hypothesis.


Keywords


duodenogastric reflux; chronic gastritis; dual prokinetic treatment

References


Mazurenko NN. Duodenogastric reflux in children: modern view on the problem]. Vestnik VGMU. 2018;17(1):23-33. doi: 10.22263/2312-4156.2018.1.23. (in Russian).

Tel’nykh YV, Abgadzhava EZ, Kon’kov MY. Biliary reflux-gastritis: etiology, pathogenesis and modern principles of treatment. Klin Med (Mosk). 2016;94(6):454-7. (in Russian).

Galiev ShZ, Amirov NB. Duodenogastric reflux as a cause of reflux-gastritis. Vestnik Sovremennoi Klinicheskoi Mediciny. 2015;8(2):50-61. (in Russian).

Zviagintseva TD, Chernobai AI. Duodenogastric reflux in the practice of a gastroenterologist: obvious dangers and hidden threat. Zdorov’ja Ukrai'ny. Gastroenterologija, Gepatologija, Koloproktologija. 2012;(23):11. (in Russian).

Mikhailusov SV, Bart BY, Mikhailusova MP, Nikolaeva AS. The biliary reflux (clinical features). Poliklinika. 2018;(4-2):28-34. (in Russian).

Mabrut JY, Collard JM, Baulieux J. Le reflux biliaire duodéno-gastrique et gastro-œsophagien. Duodenogastric and gastroesophageal bile reflux. Journal de Chirurgie. 2006 Dec ;143(6):355-365. doi: 10.1016/S0021-7697(06)73717-6. (in French).

Tatsugami M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K, Chayama K. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2101-7. doi: 10.1158/1055-9965.EPI-12-0730.

Matsuhisa T, Arakawa T, Watanabe T, et al. Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia: a multicenter study of 2283 cases. Dig Endosc. 2013 Sep;25(5):519-25. doi: 10.1111/den.12030.

Kushnirenko IV, Maikova TV, Sirotenko IA. Violations of the motor-evacuation function of the stomach. Modern methods for their correction in chronic gastroduodenitis. Review and own research. Novosti Meditsiny i Farmatsii. Gastroenterologiia. 2011;(382):13-17. (in Russian).

Anderson S, Wilkinson M. Dyspepsia: recommended investigations and treatment. Prescriber. 2010; 21(18):31-42. doi: 10.1002/psb.667.

Babak OJa, Mozhyna TL. Prokinetic drugs (from metoclopramide to itoprid) in clinical practice. Modern Gastroenterology. 2008;(43):4-11. (in Ukrainian).

Gubergrits NB. Modern prokinetics. In: Gubergrits NB. Khronicheskaia abdominal'naia bol'. Biliarnaia bol'. Bol' pri zabolevaniiakh pecheni [Chronic abdominal pain. Biliary pain. Pain in liver disease]. Donetsk: OOO Lebed'; 2006. 68-72 pp. (in Russian).

Yang YJ, Bang CS, Baik GH, et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017 Jun 26;17(1):83. doi: 10.1186/s12876-017-0639-0.

Pittayanon R, Yuan Y, Bollegala NP, Khanna R, Leontiadis GI, Moayyedi P. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev. 2018 Oct 18;10:CD009431. doi: 10.1002/14651858.CD009431.pub3.

Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol. 2019 Feb;114(2):233-243. doi: 10.1038/s41395-018-0258-6.

Tack J, Van den Houte K, Carbone F. The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome. Am J Gastroenterol. 2019 Feb;114(2):204-206. doi: 10.14309/ajg.0000000000000072.

Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol. 2007 Mar;22(3):304-10. doi: 10.1111/j.1440-1746.2006.04493.x.

Kolyutskaya EV. Role of sulpiride in the treatment of somatoform disorders. Meditsinskiy sovet. 2017;(17):20-24. doi: 10.21518/2079-701X-2017-17-20-24. (in Russian).

Gucalenko OO, Katerenchuk IP, Salo LM, et al. Therapeutic efficacy of eglonil in the complex treatment of patients with combined pathology of the gastrointestinal tract and psychosomatic disorders. In: Babak OJa, Bojko TJ, Gravirovs'ka NG, et al, authors; Filippov JuO, editor. Gastroenterologija: mizhvidomchyj zbirnyk [Gastronetrology: interdepartmental collection]. Dnipro; 2005. 617-622 pp. (in Ukrainian).

Gucalenko OO. Sposib likuvannja duodenogastral'nogo refljuksu u hvoryh na hronichnyj gastryt [Method of treatment of duodenogastric reflux in patients with chronic gastritis]. Patent UA № 110408, 2016. (in Ukrainian).

Gucalenko OO. Registry 53/4/17. Method of treatment of duodenogastric reflux in patients with chronic gastritis. In: Perelik naukovoi' (naukovo-tehnichnoi') produkcii', pryznachenoi' dlja vprovadzhennja dosjagnen' medychnoi' nauky u sferu ohorony zdorov’ja u 2017 roci [The list of scientific (scientific and technical) products intended for introducing the achievements of medical science into the healthcare sector in 2017]. Kyiv; 2018. 58-60 pp. (in Ukrainian).

Haunton V, Boovalingam P, Lo N. Managing upper gastrointestinal disorders in older people. Prescriber. 2010 Apr;21(8):45-50. doi: 10.1002/psb.620.

Lin JK, Hu PJ, Li CJ, Zeng ZR, Zhang XG. A study of diagnosis of primary biliary reflux gastritis. Zhonghua Nei Ke Za Zhi. 2003 Feb;42(2):81-3. (in Chinese).

Rebrova OIu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. Application of the STATISTICA application package]. 3rd ed. Moscow: MediaSfera; 2006. 134-184 pp. (in Russian).

Cehmister JaV, Gur'janov VG, Ljah JuJe, Parij VD, Korotkyj OV, Chalyj OV. Posibnyk z biostatystyky. Analiz rezul'tativ medychnyh doslidzhen' u paketi EZR (R–statistics): navchal'nyj posibnyk [Manual on biostatistics. Analysis of the results of medical research in the package EZR (R-statistics): a manual]. Kyiv: Vistka; 2018. 208 p. (in Ukrainian).

Glantz SA. Primer of Biostatistics. New York: McGraw-Hill, Health Professions Division; 1997. 473 p.

MedCalc Statistical Software version 18.11.6. Ostend, Belgium: MedCalc Software bvba; 2019. Available from: https://www.medcalc.org/index.php.

Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):878-81. doi: 10.1002/pds.1397.

Taylor SJ, Allan K, McWilliam H, et al. A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastric emptying: Trial of nasointestinal feeding versus nasogastric feeding plus prokinetics. Clin Nutr ESPEN. 2016 Aug;14:1-8. doi: 10.1016/j.clnesp.2016.04.020.

Baradari AG, Khajavi MR, Firouzian A, et al. Effects of combined prokinetic administration on gastric emptying in critically ill patients. Arab J Gastroenterol. 2017 Mar;18(1):30-34. doi: 10.1016/j.ajg.2017.01.007.




Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта